Firebrick Pharma Share Price and Company Fundamentals
Last traded: Today at 5:55 AM
Firebrick Pharma Limited engages in the development and commercialization of povidone-iodine (PVP-I) products under the Nasodine brand in Asia, North America, Europe, and internationally. It offers nasal spray PVP-I products for the treatment of common cold. The company was incorporated in 2012 and is based in Melbourne, Australia.
Key Metrics
PE ratio
-
PB ratio
4.00
Dividend yield
-
Beta
-
Market cap
$9.19M
Enterprise value
$7.23M
Company profile
| Industry / Sector | Drug Manufacturers - General / Healthcare |
|---|---|
| Website | https://firebrickpharma.com |
| Mailing address | Level 14 333 Collins Street Melbourne VIC Australia |
| Phone / Fax | / |
Dividends
More: Firebrick Pharma Dividend history, yield and payout ratio
Dividend yield
-
Dividend amount
$-
Payout ratio
0.00%
5Y Avg. yield
-%
Firebrick Pharma paid $- dividend and the ex-dividend date was -.The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.FRE dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of Sep 2026, following are the company executives and directors listed on Firebrick Pharma.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Dr. Peter Laurence Molloy B.Sc., F.A.C.I.D., M.B.A., Ph.D. | Founder, Executive Chairman & CEO | 71 | |
| Dr. Stephen Francis Goodall M.B.A., Ph.D. | Founder, COO & Executive Director | ||
| Mr. Kavi Bekarma B.Sc., C.A. | Chief Financial Officer | ||
| Dr. Simon Tucker B.Sc., Ph.D. | Chief Scientific Officer | ||
| Dr. Monique Baldwin B.Sc., Ph.D. | Head of Regulatory Affairs | ||
| Mr. Nilesh N. Wadhwa | Head of Business Development & Licensing | 55 | |
| Mr. Stephen Buckley | Company Secretary |
Profitability and management effectiveness
Profit margin
0.00%
Operating margin
-3322.28%
Return on assets
-92.70%
Return on equity
-189.19%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Firebrick Pharma is 9.19M and its enterprise value is 7.23M. The enterprise value to revenue ratio of FRE is 49.95. The enterprise value to EBITDA ratio of FRE is -2.44.
Companies similar to Firebrick Pharma (FRE)
Firebrick Pharma (ASX:FRE) Frequently Asked Questions
1. What is Firebrick Pharma's Stock Symbol?
Firebrick Pharma trades on ASX under the ticker symbol "FRE".
2. What is Firebrick Pharma's stock price today?
One share of FRE stock can currently be purchased for approximately $0.032.
3. How can I contact Firebrick Pharma?
Firebrick Pharma's mailing address is Level 14 333 Collins Street Melbourne VIC Australia. The company can be reached via phone at .
4. What is Firebrick Pharma's official website?
The official website of Firebrick Pharma is https://firebrickpharma.com.